ONC250117C180000
- 21.60
- 0.000.00%
BeiGene Newsroom
BEIGENE (06160) JPM 2025 releases Bullish news, multiple international investment banks remain Bullish on the company's prospects.
At the JPM Conference in 2025, BEIGENE management clearly provided guidance on the timeline for profitability, expecting to achieve GAAP operating profit break-even in 2025, one year earlier than market expectations.
BeiGene, Ltd.'s (NASDAQ:ONC) Profit Outlook
BeiGene Enters Sublease Agreement With ChemoCentryx for Expansion
BEIGENE (06160.HK) subsidiary signs a sublease agreement with Chemo Centryx.
On January 20, Gelonghui announced that BEIGENE (06160.HK) signed a sublease agreement on January 17, 2025 (USA time) between a wholly-owned subsidiary BEIGENE US (as lessee) and Chemo Centryx (as sublessor), whereby Chemo Centryx agreed to sublease the property to BEIGENE US. The lease term shall commence from the effective date of the sublease until the expiration date of the sublease. Subleased property: Approximately 96,372 square feet of rentable space, including about 49,820 square feet on the fifth floor and the sixth floor.
BeiGene Announces Board Composition and Committee Roles
BEIGENE (06160.HK): Anthony C. Hooper has been appointed as the chairman of the Nomination and Corporate Governance Committee.
On January 20, Gelonghui reported that BEIGENE (06160.HK) announced that its independent non-executive director, Ms. Shalini Sharp, has been appointed as a member of the Nomination and Corporate Governance Committee, and its independent non-executive director, Mr. Anthony C. Hooper, has been appointed as the chairman of the Nomination and Corporate Governance Committee, effective from January 16, 2025 (USA time).
China Merchants: Class B catalog will be released within the year + Commercial health Insurance provides additional payment for Innovative Drugs, further improving bulk purchasing and medical insurance prepayment.
The first version of the Category B directory is scheduled to be released within this year, and it is expected to be aligned with the annual adjustments of the medical insurance directory, contributing to the incremental increase of payments for Innovative Drugs.
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
BofA Securities Maintains BeiGene(ONC.US) With Hold Rating, Maintains Target Price $207
BeiGene Schedules EGM for Strategic Corporate Changes
US MOVERS&SHAKERS Jan 13-Jan 17, 2025
With the expectation of positive full-year operating profit due to global innovation, BEIGENE (06160) is about to showcase a "Davis Double Click."
John V. Oyler, co-founder, Chairman and CEO of BEIGENE, pointed out: After 15 years of development, BEIGENE has become an innovator in the field of oncology and has reached a critical turning point, with the company currently preparing to enter the next stage of Global growth. By 2025, BEIGENE expects to achieve positive annual Operating profit.
Network Technology continues to lead the rebound of Hong Kong stocks, and Institutions suggest paying short-term attention to this focus.
On January 16, driven by the relief of inflation concerns from the December USA CPI data and the overnight rise of the US stock market, the Hong Kong stock market continued its upward trend, with the Hang Seng Index closing at 19,522 points, up 1.2% or 236 points. The Hang Seng TECH Index reported 4,417 points, up 1.2% or 53 points. The total market turnover was 142.3 billion yuan.
[Brokerage Focus] Jianyin International raised the Target Price for BEIGENE (06160) by 3.5%, citing improved fundamentals and expects that PD-1 biologics will have a positive impact on sales.
Jinwu Finance | Jianyin International released a Research Report indicating that BEIGENE (06160) announced that it is expected to achieve operating profit under USA Generally Accepted Accounting Principles (GAAP) for the first time in the fiscal year 2025. The bank expects the group to achieve GAAP break-even in 2025 and for the first time achieve annual non-GAAP Net income. It raised the sales forecast for its BTK drugs in fiscal year 2025 by 25% and for fiscal year 2026 by 15%, resulting in forecasted sales of $3.3 billion and $4 billion respectively. Considering the improvement in BEIGENE's operation efficiency, the bank adjusted operating expenses for fiscal years 2025 and 2026.
Hong Kong stocks movement | BEIGENE (06160) rises over 4% again, expecting to achieve positive operating profit for the entire year this year.
BEIGENE (06160) has risen over 4% again, as of the time of writing, up 4.15%, trading at HKD 123.1, with a transaction volume of HKD 83.2007 million.
Top Gap Ups and Downs on Tuesday: XPEV, DB, SNAP and More
BeOne Medicines Up Over 12%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk
10 Health Care Stocks With Whale Alerts In Today's Session
U.S. stock market movements | The company expects to achieve positive operating profit in 2025, BEIGENE (ONC.US) surged over 7%.
On Tuesday, BEIGENE (ONC.US) rose by over 7%, closing at $197.77.
Hong Kong stock announcement digging gold | SHANGHAI PECHEM plans to invest approximately 21.307 billion yuan to construct a comprehensive technological transformation and quality upgrading project.
SHANGHAI PECHEM (00338) plans to invest approximately 21.307 billion yuan to build a comprehensive technological transformation and quality upgrade project; COUNTRY GARDEN (02007) released its mid-term performance for 2024, achieving revenue of approximately 102.1 billion yuan, with cumulative delivery of over 0.15 million units of housing...